Table 2 Exposure characteristics in infected and vaccinated cohortsa
 | Infected | Vaccinated |
---|---|---|
Number of pregnancies | 4074 | 11379 |
Gestation at first exposure | ||
Preconception | 220 (5.4%) | 1620 (14.2%) |
2–19 weeks | 1080 (26.5%) | 3960 (34.8%) |
≥20 weeks | 2774 (68.1%) | 5799 (51.0%) |
Number of infections during exposure period | ||
1 | 4030 (98.9%) | – |
2 | 44 (1.1%) | – |
Timing of infections (among neonates exposed to two infections in pregnancy) | ||
<20weeks | 3 (6.8%) | – |
≥20 weeks | 10 (22.7%) | – |
Both | 31 (70.5%) | – |
Number of vaccinations during exposure period | ||
1 | – | 3867 (34.0%) |
2+ | – | 7512 (66.0%) |
Vaccine type | ||
Oxford-AstraZeneca ChAdOx1-s/nCoV-19 | – | 785 (6.9%) |
Moderna mRNA-1273 | – | 1217 (10.7%) |
Pfizer-BioNTech BNT162b2 | – | 8672 (76.2%) |
Mixed Doses | – | 705 (6.2%) |